{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:01:04Z","timestamp":1792591264326,"version":"4.5.0"},"reference-count":15,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"29","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,10,10]]},"abstract":"<jats:p>\n                    <jats:italic>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in<\/jats:italic>\n                    JCO\n                    <jats:italic>or elsewhere, for which the primary end point has already been reported<\/jats:italic>\n                    .\n                  <\/jats:p>\n                  <jats:p>Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3, has shown durable anticancer activity and manageable safety in previously treated small cell lung cancer (SCLC) in DeLLphi-300 phase I and DeLLphi-301 phase II trials. Here, we report extended follow-up of DeLLphi-300 (median follow-up, 12.1 months [range, 0.2-34.3]) in fully enrolled cohorts treated with tarlatamab \u226510 mg dose administered once every two weeks, once every three weeks, or once on day 1 and once on day 8 of a 21-day cycle (N = 152). Overall, the objective response rate (ORR) was 25.0%; the median duration of response (mDOR) was 11.2 months (95% CI, 6.6 to 22.3), and the median overall survival (mOS) was 17.5 months (95% CI, 11.4 to not estimable [NE]). Among 17 patients receiving 10 mg tarlatamab once every two weeks, the ORR was 35.3%, the mDOR was 14.9 months (95% CI, 3.0 to NE), the mOS was 20.3 months (95% CI, 5.1 to NE), and 29.4% had sustained disease control with time on treatment \u226552 weeks. No new safety signals were identified. In modified Response Assessment in Neuro-Oncology Brain Metastases analyses, CNS tumor shrinkage of \u226530% was observed in 62.5% of patients (10 of 16) who had a baseline CNS lesion of \u226510 mm, including in a subset of patients with tumor shrinkage long after previous brain radiotherapy. In DeLLphi-300 extended follow-up, tarlatamab demonstrated unprecedented survival and potential findings of intracranial activity in previously treated SCLC.<\/jats:p>","DOI":"10.1200\/jco.24.00553","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:59:46Z","timestamp":1724947186000},"page":"3392-3399","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":70,"title":["Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update"],"prefix":"10.1200","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03319940","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-6839","authenticated-orcid":true,"given":"Afshin","family":"Dowlati","sequence":"first","affiliation":[{"name":"University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst-Dieter","family":"Hummel","sequence":"additional","affiliation":[{"name":"Translational Oncology\/Early Clinical Trial Unit (ECTU), Bavarian Cancer Research Center, National Center for Tumor Diseases, Comprehensive Cancer Center Mainfranken and University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-2118","authenticated-orcid":true,"given":"Stephane","family":"Champiat","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Innovation and Early Phase Trials, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Olmedo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ram\u00f3n y Cajal University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0452-2987","authenticated-orcid":true,"given":"Michael","family":"Boyer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia"},{"name":"Faculty of Medicine and Health, School of Medicine, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4378-9297","authenticated-orcid":true,"given":"Kai","family":"He","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-2279","authenticated-orcid":true,"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-4859","authenticated-orcid":true,"given":"Hiroki","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-1314","authenticated-orcid":true,"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4896-5824","authenticated-orcid":true,"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasna","family":"Bouchaab","sequence":"additional","affiliation":[{"name":"Department of Oncology, Vaud University Hospital, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-4454","authenticated-orcid":true,"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7620-0098","authenticated-orcid":true,"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario del Vall d'Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-0362","authenticated-orcid":true,"given":"Philipp J.","family":"Jost","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5240-3811","authenticated-orcid":true,"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Henry Ford Cancer Institute\/Henry Ford Health System, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3976-799X","authenticated-orcid":true,"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4986-848X","authenticated-orcid":true,"given":"Youfei","family":"Yu","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Martinez","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-6460","authenticated-orcid":true,"given":"Amanda","family":"Parkes","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-3364","authenticated-orcid":true,"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Complutense University and Ciberonc, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02823"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013122"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071780"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30230-9"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.658"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5392"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"e_1_3_9_12_2","volume-title":"IMDELLTRA\u2122 [prescribing information]","year":"2024","unstructured":"IMDELLTRA\u2122 [prescribing information]. Thousand Oaks, CA: Amgen Inc. 2024. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Imdelltra\/imdelltra_fpi.pdf"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70057-4"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8582"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0205-x"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.24.00553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T17:59:36Z","timestamp":1728323976000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.00553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":15,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2024,10,10]]}},"alternative-id":["10.1200\/JCO.24.00553"],"URL":"https:\/\/doi.org\/10.1200\/jco.24.00553","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"2024-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}